{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:25:36Z","timestamp":1792700736905,"version":"4.5.0"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008294","name":"Louisiana State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20GM130555-Sub#6610"],"award-info":[{"award-number":["P20GM130555-Sub#6610"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI117408"],"award-info":[{"award-number":["R01AI117408"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL144661"],"award-info":[{"award-number":["R01HL144661"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI138497"],"award-info":[{"award-number":["R21AI138497"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI137822"],"award-info":[{"award-number":["R21AI137822"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI129422"],"award-info":[{"award-number":["R21AI129422"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL125749"],"award-info":[{"award-number":["R01HL125749"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30GM110760"],"award-info":[{"award-number":["P30GM110760"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["6610"],"award-info":[{"award-number":["6610"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012429","name":"School of Veterinary Medicine, Louisiana State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006646","name":"Department of Veterinary Medicine, Cambridge Veterinary School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.pharmthera.2019.107453","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T20:07:50Z","timestamp":1576008470000},"page":"107453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":173,"special_numbering":"C","title":["Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery"],"prefix":"10.1016","volume":"207","author":[{"given":"Natalie F.","family":"Nidetz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"McGee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longping V.","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weishan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2019.107453_bb0005","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s12640-014-9514-8","article-title":"Toxic effects of bortezomib on primary sensory neurons and Schwann cells of adult mice","volume":"27","author":"Ale","year":"2015","journal-title":"Neurotoxicity Research"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.neuro.2014.02.001","article-title":"Neurotoxicity induced by antineoplastic proteasome inhibitors","volume":"43","author":"Ale","year":"2014","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0015","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/mt.2011.287","article-title":"The AAV vector toolkit: Poised at the clinical crossroads","volume":"20","author":"Asokan","year":"2012","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0020","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-associated defective virus particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1566523214666140302193709","article-title":"Basic biology of adeno-associated virus (AAV) vectors used in gene therapy","volume":"14","author":"Balakrishnan","year":"2014","journal-title":"Current Gene Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053845","article-title":"Activation of the cellular unfolded protein response by recombinant adeno-associated virus vectors","volume":"8","author":"Balakrishnan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0035","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.virol.2011.01.019","article-title":"Lysosomal localization and mechanism of membrane penetration influence nonenveloped virus activation of the NLRP3 inflammasome","volume":"412","author":"Barlan","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0040","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1128\/JVI.01265-10","article-title":"Adenovirus membrane penetration activates the NLRP3 inflammasome","volume":"85","author":"Barlan","year":"2011","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0045","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fmicb.2011.00204","article-title":"Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity","volume":"2","author":"Bartel","year":"2011","journal-title":"Frontiers in Microbiology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0050","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1128\/JVI.74.6.2777-2785.2000","article-title":"Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors","volume":"74","author":"Bartlett","year":"2000","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0055","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127008","article-title":"Dual muscle-liver transduction imposes immune tolerance for muscle transgene engraftment despite preexisting immunity","volume":"4","author":"Bartolo","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0060","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.smim.2007.01.003","article-title":"Viral recognition by toll-like receptors","volume":"19","author":"Barton","year":"2007","journal-title":"Seminars in Immunology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0065","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3389\/fimmu.2014.00350","article-title":"Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions","volume":"5","author":"Basner-Tschakarjan","year":"2014","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0070","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2337\/diabetes.55.01.06.db05-0613","article-title":"Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance","volume":"55","author":"Battaglia","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0075","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.4049\/jimmunol.177.12.8338","article-title":"Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients","volume":"177","author":"Battaglia","year":"2006","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0080","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2174\/1566523215666150630121750","article-title":"The skeletal muscle environment and its role in immunity and tolerance to AAV vector-mediated gene transfer","volume":"15","author":"Boisgerault","year":"2015","journal-title":"Current Gene Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0085","doi-asserted-by":"crossref","first-page":"16363","DOI":"10.1073\/pnas.0904514106","article-title":"Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy","volume":"106","author":"Brantly","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0090","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/hep.23043","article-title":"Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver","volume":"50","author":"Breous","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.immuni.2017.01.003","article-title":"CD8(+) T cells orchestrate pDC-XCR1(+) dendritic cell spatial and functional cooperativity to optimize priming","volume":"46","author":"Brewitz","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/clim.1999.4724","article-title":"Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration","volume":"92","author":"Brockstedt","year":"1999","journal-title":"Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/emmm.201202291","article-title":"Gene therapy enters the pharma market: The short story of a long journey","volume":"5","author":"Buning","year":"2013","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0110","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1089\/hgtb.2018.038","article-title":"Assessment of humoral, innate, and T-cell immune responses to adeno-associated virus vectors","volume":"29","author":"Calcedo","year":"2018","journal-title":"Human Gene Therapy Methods"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0115","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/CVI.05107-11","article-title":"Adeno-associated virus antibody profiles in newborns, children, and adolescents","volume":"18","author":"Calcedo","year":"2011","journal-title":"Clinical and Vaccine Immunology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0120","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0125","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2007-02-073304","article-title":"Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer","volume":"110","author":"Cao","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0130","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1084\/jem.184.2.747","article-title":"Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation","volume":"184","author":"Cella","year":"1996","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0135","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nmeth.3993","article-title":"A multifunctional AAV-CRISPR-Cas9 and its host response","volume":"13","author":"Chew","year":"2016","journal-title":"Nature Methods"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0140","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/mt.2013.244","article-title":"Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery","volume":"22","author":"Chicoine","year":"2014","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0145","first-page":"87","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Molecular Therapy: Methods & Clinical Development"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0150","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0155","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1089\/hum.2008.161","article-title":"Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer","volume":"20","author":"Cooper","year":"2009","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0160","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2008-02-138073","article-title":"Activation of natural regulatory T cells by IgG fc-derived peptide \"Tregitopes\"","volume":"112","author":"De Groot","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0165","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.gt.3302527","article-title":"Intracellular trafficking of adeno-associated viral vectors","volume":"12","author":"Ding","year":"2005","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0170","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2217\/fvl.13.112","article-title":"Adeno-associated virus structural biology as a tool in vector development","volume":"8","author":"Drouin","year":"2013","journal-title":"Future Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0175","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.vaccine.2008.01.025","article-title":"Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection","volume":"26","author":"Du","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0180","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1172\/JCI8317","article-title":"Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus","volume":"105","author":"Duan","year":"2000","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0185","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/(SICI)1096-9071(199911)59:3<406::AID-JMV22>3.0.CO;2-N","article-title":"Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)","volume":"59","author":"Erles","year":"1999","journal-title":"Journal of Medical Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0190","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted adeno-associated virus vectors evade immune detection","volume":"123","author":"Faust","year":"2013","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/mt.2009.257","article-title":"Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction","volume":"18","author":"Finn","year":"2010","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0200","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1089\/hum.2011.053","article-title":"Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: Interim results","volume":"22","author":"Flotte","year":"2011","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0205","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1073\/pnas.0937739100","article-title":"Adeno-associated viruses undergo substantial evolution in primates during natural infections","volume":"100","author":"Gao","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0210","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","article-title":"Clades of adeno-associated viruses are widely disseminated in human tissues","volume":"78","author":"Gao","year":"2004","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0215","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1089\/hum.2009.060","article-title":"Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses","volume":"20","author":"Gao","year":"2009","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0220","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0225","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/gt.2012.43","article-title":"Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: An open-label trial","volume":"20","author":"Gaudet","year":"2013","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0230","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2174\/1566523054064977","article-title":"Helper functions required for wild type and recombinant adeno-associated virus growth","volume":"5","author":"Geoffroy","year":"2005","journal-title":"Current Gene Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0235","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/B978-0-12-386509-0.00012-0","article-title":"Adeno-associated virus vectorology, manufacturing, and clinical applications","volume":"507","author":"Grieger","year":"2012","journal-title":"Methods in Enzymology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0240","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.1016\/j.biomaterials.2014.05.032","article-title":"Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo","volume":"35","author":"Gyorgy","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0245","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ymthe.2016.12.010","article-title":"Rescue of Hearing by gene delivery to inner-ear hair cells using exosome-associated AAV","volume":"25","author":"Gyorgy","year":"2017","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0250","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.tim.2008.01.012","article-title":"The parvovirus capsid odyssey: From the cell surface to the nucleus","volume":"16","author":"Harbison","year":"2008","journal-title":"Trends in Microbiology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0255","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/hum.2013.065","article-title":"Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical","volume":"24","author":"He","year":"2013","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0260","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/mt.2015.135","article-title":"Hemophilia gene therapy: Caught between a cure and an immune response","volume":"23","author":"Herzog","year":"2015","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2017.05.006","article-title":"Complexity of immune responses to AAV transgene products - example of factor IX","volume":"342","author":"Herzog","year":"2019","journal-title":"Cellular Immunology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0270","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/mt.2011.33","article-title":"Nonredundant roles of IL-10 and TGF-beta in suppression of immune responses to hepatic AAV-factor IX gene transfer","volume":"19","author":"Hoffman","year":"2011","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0275","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/hep.24625","article-title":"Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors","volume":"55","author":"Hosel","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0280","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene abeparvovec: First global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0285","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/mt.2013.166","article-title":"Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes","volume":"21","author":"Hui","year":"2013","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0290","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/mt.2011.111","article-title":"Engineering biomaterial systems to enhance viral vector gene delivery","volume":"19","author":"Jang","year":"2011","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0295","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0300","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molmed.2007.09.002","article-title":"Signaling to NF-kappaB by toll-like receptors","volume":"13","author":"Kawai","year":"2007","journal-title":"Trends in Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0305","article-title":"In vivo genome editing with a small Cas9 orthologue derived from campylobacter jejuni","volume":"8","author":"Kim","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0310","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrg3742","article-title":"Engineering adeno-associated viruses for clinical gene therapy","volume":"15","author":"Kotterman","year":"2014","journal-title":"Nature Reviews. Genetics"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0315","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1182\/blood-2008-07-171637","article-title":"Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors","volume":"113","author":"Kuhn","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0320","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.ymthe.2017.02.014","article-title":"The balance between CD8(+) T cell-mediated clearance of AAV-encoded antigen in the liver and tolerance is dependent on the vector dose","volume":"25","author":"Kumar","year":"2017","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0325","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1172\/JCI122372","article-title":"Exposure to wild-type AAV drives distinct capsid immunity profiles in humans","volume":"128","author":"Kuranda","year":"2018","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0330","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1128\/JVI.02702-13","article-title":"Adenovirus detection by the cGAS\/STING\/TBK1 DNA sensing cascade","volume":"88","author":"Lam","year":"2014","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0335","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/bit.20562","article-title":"PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization","volume":"92","author":"Lee","year":"2005","journal-title":"Biotechnology and Bioengineering"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0340","first-page":"111","article-title":"A self-deleting AAV-CRISPR system for in vivo genome editing","volume":"12","author":"Li","year":"2019","journal-title":"Molecular Therapy: Methods & Clinical Development"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0345","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1172\/JCI66611","article-title":"Adeno-associated virus capsid antigen presentation is dependent on endosomal escape","volume":"123","author":"Li","year":"2013","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0350","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/gt.2011.90","article-title":"Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia","volume":"19","author":"Li","year":"2012","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0355","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1038\/mt.2011.81","article-title":"Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates","volume":"19","author":"Li","year":"2011","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0360","doi-asserted-by":"crossref","first-page":"12738","DOI":"10.1128\/JVI.01441-09","article-title":"A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque","volume":"83","author":"Lin","year":"2009","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0365","first-page":"3958","article-title":"Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice","volume":"117","author":"Lin","year":"2007","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0370","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ijc.20530","article-title":"Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody","volume":"113","author":"Liu","year":"2005","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0375","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.immuni.2010.10.004","article-title":"Immunologic basis of vaccine vectors","volume":"33","author":"Liu","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0380","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2144\/03341dd07","article-title":"Optimized production of high-titer recombinant adeno-associated virus in roller bottles","volume":"34","author":"Liu","year":"2003","journal-title":"Biotechniques"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0385","doi-asserted-by":"crossref","first-page":"17158","DOI":"10.1073\/pnas.0909520106","article-title":"Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors","volume":"106","author":"Lu","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0390","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","article-title":"Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10","volume":"25","author":"Maeder","year":"2019","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0395","doi-asserted-by":"crossref","first-page":"7960","DOI":"10.1128\/jvi.71.10.7960-7962.1997","article-title":"Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D","volume":"71","author":"Manning","year":"1997","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0400","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0405","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/emmm.201302859","article-title":"Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies","volume":"5","author":"Markusic","year":"2013","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0410","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2012-10-460733","article-title":"Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells","volume":"121","author":"Martino","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0415","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","article-title":"The genome of self-complementary adeno-associated viral vectors increases toll-like receptor 9-dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0420","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.4049\/jimmunol.0803965","article-title":"Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins","volume":"182","author":"Mays","year":"2009","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0425","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/mt.2013.134","article-title":"AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells","volume":"22","author":"Mays","year":"2014","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0430","doi-asserted-by":"crossref","first-page":"9473","DOI":"10.1128\/JVI.00596-13","article-title":"Mapping the structural determinants responsible for enhanced T cell activation to the immunogenic adeno-associated virus capsid from isolate rhesus 32.33","volume":"87","author":"Mays","year":"2013","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0435","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/mt.2010.250","article-title":"The complex and evolving story of T cell activation to AAV vector-encoded transgene products","volume":"19","author":"Mays","year":"2011","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0440","doi-asserted-by":"crossref","first-page":"10806","DOI":"10.1128\/JVI.00675-11","article-title":"Adenovirus type 5 rupture of lysosomes leads to cathepsin B-dependent mitochondrial stress and production of reactive oxygen species","volume":"85","author":"McGuire","year":"2011","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0445","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/bloodadvances.2017010181","article-title":"Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors","volume":"1","author":"Meliani","year":"2017","journal-title":"Blood Advances"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0450","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0455","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/jb.90.1.271-274.1965","article-title":"Association of 20-Millimicron particles with adenoviruses","volume":"90","author":"Melnick","year":"1965","journal-title":"Journal of Bacteriology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0460","doi-asserted-by":"crossref","first-page":"194ra192","DOI":"10.1126\/scitranslmed.3005795","article-title":"Overcoming preexisting humoral immunity to AAV using capsid decoys","volume":"5","author":"Mingozzi","year":"2013","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0465","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrg2988","article-title":"Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges","volume":"12","author":"Mingozzi","year":"2011","journal-title":"Nature Reviews. Genetics"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0470","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: Overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0475","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0480","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0485","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2008-07-167510","article-title":"AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells","volume":"114","author":"Mingozzi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0490","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/mt.2010.170","article-title":"Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: A strategy for broad clinical application","volume":"18","author":"Monahan","year":"2010","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0495","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/mt.2011.108","article-title":"A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8","volume":"19","author":"Monteilhet","year":"2011","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0500","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1172\/JCI70314","article-title":"Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression","volume":"123","author":"Mueller","year":"2013","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0505","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/d41573-019-00139-z","article-title":"First in vivo CRISPR candidate enters the clinic","volume":"18","author":"Mullard","year":"2019","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0510","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1128\/JVI.75.15.6969-6976.2001","article-title":"Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo","volume":"75","author":"Nakai","year":"2001","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0515","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/gt.2008.137","article-title":"Enhancing transduction of the liver by adeno-associated viral vectors","volume":"16","author":"Nathwani","year":"2009","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0520","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1182\/blood-2006-03-010181","article-title":"Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates","volume":"109","author":"Nathwani","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0525","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0530","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins","volume":"19","author":"Nathwani","year":"2011","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0535","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0540","doi-asserted-by":"crossref","first-page":"7765","DOI":"10.1073\/pnas.0510484103","article-title":"Loss of Siglec expression on T lymphocytes during human evolution","volume":"103","author":"Nguyen","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0545","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2008-10-181479","article-title":"Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy","volume":"113","author":"Niemeyer","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0550","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fimmu.2014.00005","article-title":"AAV vectors vaccines against infectious diseases","volume":"5","author":"Nieto","year":"2014","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0555","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.chom.2011.10.014","article-title":"Adeno-associated virus 2 infection requires endocytosis through the CLIC\/GEEC pathway","volume":"10","author":"Nonnenmacher","year":"2011","journal-title":"Cell Host & Microbe"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0560","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.molimm.2012.10.005","article-title":"Importance of TAP-independent processing pathways","volume":"55","author":"Oliveira","year":"2013","journal-title":"Molecular Immunology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0565","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0570","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3389\/fimmu.2018.00844","article-title":"Efficient capsid antigen presentation from adeno-associated virus empty Virions in vivo","volume":"9","author":"Pei","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0575","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nature13818","article-title":"Mitochondrial UPR-regulated innate immunity provides resistance to pathogen infection","volume":"516","author":"Pellegrino","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0580","first-page":"166","article-title":"Pharmacology of recombinant adeno-associated virus production","volume":"8","author":"Penaud-Budloo","year":"2018","journal-title":"Molecular Therapy: Methods & Clinical Development"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0585","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1172\/JCI36891","article-title":"Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors","volume":"119","author":"Pien","year":"2009","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0590","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis699","article-title":"Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines","volume":"207","author":"Ploquin","year":"2013","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0595","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0600","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/30989","article-title":"A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell","volume":"393","author":"Ridge","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0605","doi-asserted-by":"crossref","DOI":"10.1002\/biot.201600193","article-title":"Manufacturing of recombinant adeno-associated viruses using mammalian expression platforms","volume":"12","author":"Robert","year":"2017","journal-title":"Biotechnology Journal"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0610","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fmicb.2011.00194","article-title":"Innate immune responses to AAV vectors","volume":"2","author":"Rogers","year":"2011","journal-title":"Frontiers in Microbiology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0615","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1182\/blood-2016-11-751040","article-title":"Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8(+) T cells","volume":"129","author":"Rogers","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0620","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000369273","article-title":"Unique roles of TLR9- and MyD88-dependent and -independent pathways in adaptive immune responses to AAV-mediated gene transfer","volume":"7","author":"Rogers","year":"2015","journal-title":"Journal of Innate Immunity"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0625","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.0105-2896.2006.00420.x","article-title":"Interleukin-10-secreting type 1 regulatory T cells in rodents and humans","volume":"212","author":"Roncarolo","year":"2006","journal-title":"Immunological Reviews"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000503","article-title":"Isolation and characterization of adenoviruses persistently shed from the gastrointestinal tract of non-human primates","volume":"5","author":"Roy","year":"2009","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0635","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0640","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/JVI.75.1.269-277.2001","article-title":"Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors","volume":"75","author":"Sarukhan","year":"2001","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0645","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1073\/pnas.0800928105","article-title":"T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR","volume":"105","author":"Sauer","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0650","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.4049\/jimmunol.168.11.5521","article-title":"Peptide antigen priming of naive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12","volume":"168","author":"Schmidt","year":"2002","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0655","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1084\/jem.192.1.145","article-title":"Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli","volume":"192","author":"Schuurhuis","year":"2000","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0660","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120474","article-title":"Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction","volume":"3","author":"Shao","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0665","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1128\/JVI.00331-09","article-title":"Cryo-electron microscopy structure of adenovirus type 2 temperature-sensitive mutant 1 reveals insight into the cell entry defect","volume":"83","author":"Silvestry","year":"2009","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0670","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.4049\/jimmunol.175.9.6107","article-title":"The IL-4 receptor alpha-chain-binding cytokines, IL-4 and IL-13, induce forkhead box P3-expressing CD25+CD4+ regulatory T cells from CD25-CD4+ precursors","volume":"175","author":"Skapenko","year":"2005","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0675","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/gt.2008.55","article-title":"Adeno-associated virus integration: Virus versus vector","volume":"15","author":"Smith","year":"2008","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0680","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0685","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature06013","article-title":"DAI (DLM-1\/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response","volume":"448","author":"Takaoka","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0690","first-page":"E4812","article-title":"Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion","volume":"114","author":"Tse","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0695","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1517\/14712598.2015.1035645","article-title":"Strategies to circumvent humoral immunity to adeno-associated viral vectors","volume":"15","author":"Tse","year":"2015","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0700","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1126\/science.aal3204","article-title":"Can T cells be too exhausted to fight back?","volume":"354","author":"Turner","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0705","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3389\/fimmu.2013.00468","article-title":"Sensing microbial RNA in the cytosol","volume":"4","author":"Vabret","year":"2013","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0710","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1038\/mt.2012.220","article-title":"rAAV-mediated tumorigenesis: Still unresolved after an AAV assault","volume":"20","author":"Valdmanis","year":"2012","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0715","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nm1445","article-title":"Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid","volume":"12","author":"Vandenberghe","year":"2006","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0720","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1538-7836.2006.02220.x","article-title":"Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy","volume":"5","author":"Vandendriessche","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0725","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/sj.gt.3302539","article-title":"Major role of local immune responses in antibody formation to factor IX in AAV gene transfer","volume":"12","author":"Wang","year":"2005","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0730","first-page":"1","article-title":"Adeno-associated virus biology","volume":"807","author":"Weitzman","year":"2011","journal-title":"Methods in Molecular Biology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0735","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/gt.2008.65","article-title":"Manufacturing and characterizing AAV-based vectors for use in clinical studies","volume":"15","author":"Wright","year":"2008","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0740","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/mt.2013.218","article-title":"CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome","volume":"22","author":"Wu","year":"2014","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0745","doi-asserted-by":"crossref","first-page":"11899","DOI":"10.1128\/JVI.00890-06","article-title":"Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells","volume":"80","author":"Xin","year":"2006","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0750","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1089\/10430340260201662","article-title":"Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses","volume":"13","author":"Xin","year":"2002","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0755","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1089\/104303401750214276","article-title":"A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus","volume":"12","author":"Xin","year":"2001","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0760","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1128\/jvi.76.5.2043-2053.2002","article-title":"Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors","volume":"76","author":"Yan","year":"2002","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0765","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd.2016.280","article-title":"Delivery technologies for genome editing","volume":"16","author":"Yin","year":"2017","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0770","first-page":"2197","article-title":"CRISPR\/Cas9-mediated cervical cancer treatment targeting human papillomavirus E6","volume":"17","author":"Yoshiba","year":"2019","journal-title":"Oncology Letters"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0775","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/JVI.01990-07","article-title":"Complement is an essential component of the immune response to adeno-associated virus vectors","volume":"82","author":"Zaiss","year":"2008","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0780","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1128\/JVI.76.9.4580-4590.2002","article-title":"Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors","volume":"76","author":"Zaiss","year":"2002","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0785","doi-asserted-by":"crossref","first-page":"7827","DOI":"10.1073\/pnas.0802866105","article-title":"Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses","volume":"105","author":"Zhong","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0790","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/sj.mt.6300170","article-title":"A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis","volume":"15","author":"Zhong","year":"2007","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0795","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1128\/JVI.02192-06","article-title":"Innate immune response to adenoviral vectors is mediated by both toll-like receptor-dependent and -independent pathways","volume":"81","author":"Zhu","year":"2007","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2019.107453_bb0800","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"The Journal of Clinical Investigation"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819302050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819302050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:04:21Z","timestamp":1777493061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725819302050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":160,"alternative-id":["S0163725819302050"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107453","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107453"}}